JP2016510340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510340A5 JP2016510340A5 JP2015557221A JP2015557221A JP2016510340A5 JP 2016510340 A5 JP2016510340 A5 JP 2016510340A5 JP 2015557221 A JP2015557221 A JP 2015557221A JP 2015557221 A JP2015557221 A JP 2015557221A JP 2016510340 A5 JP2016510340 A5 JP 2016510340A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cannabinoids
- affinity
- tablet
- dimethylheptyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763630P | 2013-02-12 | 2013-02-12 | |
| US61/763,630 | 2013-02-12 | ||
| US201361837743P | 2013-06-21 | 2013-06-21 | |
| US61/837,743 | 2013-06-21 | ||
| PCT/US2014/016050 WO2014127016A2 (en) | 2013-02-12 | 2014-02-12 | Ultrapure tetrahydrocannabinol-11-oic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178162A Division JP2019031505A (ja) | 2013-02-12 | 2018-09-22 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510340A JP2016510340A (ja) | 2016-04-07 |
| JP2016510340A5 true JP2016510340A5 (https=) | 2017-03-16 |
| JP6689078B2 JP6689078B2 (ja) | 2020-04-28 |
Family
ID=51354671
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557221A Expired - Fee Related JP6689078B2 (ja) | 2013-02-12 | 2014-02-12 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| JP2018178162A Pending JP2019031505A (ja) | 2013-02-12 | 2018-09-22 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| JP2021133797A Pending JP2021185166A (ja) | 2013-02-12 | 2021-08-19 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178162A Pending JP2019031505A (ja) | 2013-02-12 | 2018-09-22 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| JP2021133797A Pending JP2021185166A (ja) | 2013-02-12 | 2021-08-19 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20150141501A1 (https=) |
| EP (2) | EP3851101A1 (https=) |
| JP (3) | JP6689078B2 (https=) |
| KR (2) | KR20190139327A (https=) |
| CN (2) | CN110946854A (https=) |
| AU (2) | AU2014216440B2 (https=) |
| BR (1) | BR112015019180A8 (https=) |
| CA (1) | CA2900982C (https=) |
| WO (1) | WO2014127016A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190139327A (ko) | 2013-02-12 | 2019-12-17 | 코버스 파마수티컬스, 아이엔씨. | 초고순도 테트라하이드로카나비놀-11-오익산 |
| CA3022391A1 (en) * | 2016-04-29 | 2017-11-02 | Corbus Pharmaceuticals, Inc. | Methods for the treatment of infection |
| US20190224118A1 (en) * | 2016-07-11 | 2019-07-25 | Intec Pharma Ltd. | Oral gastroretentive formulations and uses thereof |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| BR112020024210A2 (pt) * | 2018-05-31 | 2021-02-17 | Corbus Pharmaceuticals, Inc. | canabinoides e seus usos |
| CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US20200121614A1 (en) * | 2018-10-18 | 2020-04-23 | Bluegrass Farmacueticals, LLC | Cannabinoid-infused transparent hydrogel skin patch |
| WO2020183456A1 (en) * | 2019-03-10 | 2020-09-17 | Bol Pharma Ltd. | Cannabinoid combinations for treating chronic pain in dialysis patients |
| WO2021072325A1 (en) | 2019-10-11 | 2021-04-15 | Corbus Pharmaceuticals, Inc. | Compositions of ajulemic acid and uses thereof |
| AR123027A1 (es) * | 2020-07-21 | 2022-10-26 | Np Pharma Holdings Llc | Composiciones y métodos de cannabinoides para el tratamiento del dolor y la inflamación de las articulaciones |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2186485B (en) | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
| US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| US8586767B2 (en) | 1999-03-22 | 2013-11-19 | Craig Rick Travis | Method for treatment of HIV and diseases of immune dysregulation |
| US6974835B2 (en) | 2000-05-17 | 2005-12-13 | Indevus Pharmaceuticals, Inc. | Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7399872B2 (en) * | 2001-03-07 | 2008-07-15 | Webster G R Barrie | Conversion of CBD to Δ8-THC and Δ9-THC |
| IL153277A0 (en) * | 2002-12-04 | 2003-07-06 | Pharmos Corp | High enantiomeric purity dexanabinol for pharmaceutical compositions |
| JP2006509038A (ja) * | 2002-12-04 | 2006-03-16 | ファーモス コーポレイション | 医薬組成物用の高エナンチオマー純度を有するデキサナビノール |
| AU2003297074A1 (en) | 2002-12-13 | 2004-07-09 | Euro-Celtique S.A. | Transdermal buprenorphine to treat pain in sickle cell crisis |
| AU2003303376A1 (en) | 2002-12-19 | 2004-07-22 | University Of Massachusetts | Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators |
| US20050070596A1 (en) | 2003-05-12 | 2005-03-31 | David Baker | Methods for treatment of inflammatory diseases using CT-3 or analogs thereof |
| US20050009903A1 (en) * | 2003-06-10 | 2005-01-13 | Martin Billy R. | CB2-selective cannabinoid analogues |
| AU2006240490A1 (en) | 2005-04-21 | 2006-11-02 | Paladin Labs (Barbados) Inc. | Process for the preparation of ultrapure 4-methylprazole |
| TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| US20070037873A1 (en) | 2005-08-08 | 2007-02-15 | Zurier Robert B | Airway remodeling treatments |
| WO2007032962A2 (en) | 2005-09-09 | 2007-03-22 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| WO2007055806A1 (en) * | 2005-10-31 | 2007-05-18 | Indevus Pharmaceuticals, Inc. | Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids |
| GB2432312A (en) * | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
| PT1903866E (pt) | 2005-11-07 | 2016-06-09 | Murty Pharmaceuticals Inc | Distribuição melhorada de tetra-hidrocanabinol |
| US20080054300A1 (en) * | 2006-06-30 | 2008-03-06 | Philip Gene Nikkel | Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| US8044071B2 (en) | 2007-10-18 | 2011-10-25 | Abbott Laboratories | Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist |
| US9192598B2 (en) | 2008-06-25 | 2015-11-24 | University Of North Texas Health Science Center At Fort Worth | Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems |
| US8877188B2 (en) | 2010-05-04 | 2014-11-04 | The Brigham And Women's Hospital, Inc. | Detection and treatment of non-dermal fibrosis |
| US20130338220A1 (en) | 2010-10-05 | 2013-12-19 | Mark Tepper | Compositions, dosages, and methods of using tetrahydrocannabinol derivatives |
| US20120309820A1 (en) * | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| KR20190139327A (ko) * | 2013-02-12 | 2019-12-17 | 코버스 파마수티컬스, 아이엔씨. | 초고순도 테트라하이드로카나비놀-11-오익산 |
| US20150328198A1 (en) | 2014-05-16 | 2015-11-19 | The University Of North Carolina At Chapel Hill | Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists |
-
2014
- 2014-02-12 KR KR1020197036267A patent/KR20190139327A/ko not_active Ceased
- 2014-02-12 JP JP2015557221A patent/JP6689078B2/ja not_active Expired - Fee Related
- 2014-02-12 EP EP20208635.1A patent/EP3851101A1/en not_active Withdrawn
- 2014-02-12 EP EP14752090.2A patent/EP2956133A4/en not_active Withdrawn
- 2014-02-12 AU AU2014216440A patent/AU2014216440B2/en not_active Ceased
- 2014-02-12 CA CA2900982A patent/CA2900982C/en active Active
- 2014-02-12 BR BR112015019180A patent/BR112015019180A8/pt not_active Application Discontinuation
- 2014-02-12 CN CN201911271506.5A patent/CN110946854A/zh active Pending
- 2014-02-12 CN CN201480020828.1A patent/CN105228613A/zh active Pending
- 2014-02-12 WO PCT/US2014/016050 patent/WO2014127016A2/en not_active Ceased
- 2014-02-12 KR KR1020157024773A patent/KR20160002709A/ko not_active Ceased
- 2014-11-18 US US14/546,116 patent/US20150141501A1/en not_active Abandoned
-
2016
- 2016-07-26 US US15/220,127 patent/US10085964B2/en active Active
- 2016-11-09 US US15/347,104 patent/US9820964B2/en not_active Expired - Fee Related
- 2016-11-09 US US15/347,059 patent/US9801849B2/en not_active Expired - Fee Related
-
2017
- 2017-09-07 US US15/698,544 patent/US10154986B2/en active Active
-
2018
- 2018-09-22 JP JP2018178162A patent/JP2019031505A/ja active Pending
- 2018-11-05 AU AU2018258159A patent/AU2018258159B2/en not_active Ceased
- 2018-11-21 US US16/198,381 patent/US10369131B2/en active Active
-
2019
- 2019-05-29 US US16/425,196 patent/US11052066B2/en not_active Expired - Fee Related
-
2021
- 2021-06-02 US US17/336,759 patent/US20220117931A1/en not_active Abandoned
- 2021-08-19 JP JP2021133797A patent/JP2021185166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510340A5 (https=) | ||
| Park et al. | Resolving TRPV1-and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1 | |
| van Laar et al. | Pain treatment in arthritis-related pain: beyond NSAIDs | |
| JP2023153783A (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| Jia et al. | Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways | |
| KR101546031B1 (ko) | Ｃｍｔ 및 관련 장애를 치료하기 위한 신규 치료적 접근법 | |
| Contarini et al. | A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis | |
| Dentesano et al. | Inhibition of CD200R1 expression by C/EBP beta in reactive microglial cells | |
| Chen et al. | Receptor and molecular targets for the development of novel opioid and non-opioid analgesic therapies | |
| CN109310769B (zh) | 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗 | |
| US20200009077A1 (en) | Compositions for treating dermatological diseases | |
| JP6175054B2 (ja) | ヒストンアセチルトランスフェラーゼ活性剤の使用 | |
| US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | |
| Kim et al. | Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs | |
| CN113557022A (zh) | 用罗达司他乙酯治疗肺动脉高压的给药方案和方法 | |
| Santoro et al. | Effect of diazoxide on Friedreich ataxia models | |
| Katsuki | Nuclear receptors of NR1 and NR4 subfamilies in the regulation of microglial functions and pathology | |
| de Souza et al. | Intraarticular monomethyl fumarate as a perspective therapy for osteoarthritis by macrophage polarization | |
| WO2002024190A1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur | |
| Sonvico et al. | Drug delivery to the brain: how can nanoencapsulated statins be used in the clinic? | |
| CN109350616B (zh) | I-brd9或其衍生物在制备抗癫痫药物中的应用 | |
| WO2007054348A1 (de) | Neue arzneimittel | |
| JP6483627B2 (ja) | 脳内アミロイドβ蓄積症の予防または治療剤 | |
| JP2025513474A (ja) | 好中球性皮膚疾患の治療 | |
| Eads et al. | Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokines |